Fig. 4From: The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitorsComparison of the incidence of specific types of serious immune-related adverse events (irSAEs) between published RCTs and corresponding results posted on ClinicalTrials.gov (CT.gov)Back to article page